deltatrials
Completed PHASE1 INTERVENTIONAL 1-arm NCT03006887

Phase 1b Trial of Lenvatinib Plus Pembrolizumab in Participants With Selected Solid Tumors

An Open-Label Phase 1b Trial of Lenvatinib Plus Pembrolizumab in Subjects With Selected Solid Tumors

Sponsor: Eisai Co., Ltd.

Conditions Solid Tumors
Interventions lenvatinib pembrolizumab
Updated 21 times since 2017 Last updated: May 19, 2021 Started: Jan 12, 2017 Primary completion: Apr 15, 2020 Completion: Apr 15, 2020
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03006887, this PHASE1 trial focuses on Solid Tumors and remains completed. Sponsored by Eisai Co., Ltd., it has been updated 21 times since 2017, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~May 2017 · 3 months · monthly snapshot~May 2017 – ~Jun 2017 · 31 days · monthly snapshot~Jun 2017 – ~Mar 2018 · 9 months · monthly snapshot~Mar 2018 – ~Jun 2018 · 3 months · monthly snapshot~Jun 2018 – ~Aug 2018 · 2 months · monthly snapshot~Aug 2018 – ~Sep 2018 · 31 days · monthly snapshot~Sep 2018 – ~Dec 2018 · 3 months · monthly snapshot~Dec 2018 – ~Feb 2019 · 2 months · monthly snapshot~Feb 2019 – ~Apr 2019 · 59 days · monthly snapshot~Apr 2019 – ~May 2019 · 30 days · monthly snapshot~May 2019 – ~Jan 2020 · 8 months · monthly snapshot~Jan 2020 – ~Mar 2020 · 2 months · monthly snapshot~Mar 2020 – ~Jun 2020 · 3 months · monthly snapshot~Jun 2020 – ~Jul 2020 · 30 days · monthly snapshot~Jul 2020 – ~Jan 2021 · 6 months · monthly snapshot~Jan 2021 – ~Jun 2021 · 5 months · monthly snapshot~Jun 2021 – ~Jun 2022 · 12 months · monthly snapshot~Jun 2022 – ~Jul 2024 · 25 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 24 months · monthly snapshot

Change History

21 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  3. Jun 2022 — Jul 2024 [monthly]

    Completed PHASE1

  4. Jun 2021 — Jun 2022 [monthly]

    Completed PHASE1

  5. Jan 2021 — Jun 2021 [monthly]

    Completed PHASE1

▶ Show 16 earlier versions

  1. Jul 2020 — Jan 2021 [monthly]

    Completed PHASE1

  2. Jun 2020 — Jul 2020 [monthly]

    Completed PHASE1

    Status: Active Not Recruiting → Completed

  3. Mar 2020 — Jun 2020 [monthly]

    Active Not Recruiting PHASE1

  4. Jan 2020 — Mar 2020 [monthly]

    Active Not Recruiting PHASE1

  5. May 2019 — Jan 2020 [monthly]

    Active Not Recruiting PHASE1

  6. Apr 2019 — May 2019 [monthly]

    Active Not Recruiting PHASE1

  7. Feb 2019 — Apr 2019 [monthly]

    Active Not Recruiting PHASE1

  8. Dec 2018 — Feb 2019 [monthly]

    Active Not Recruiting PHASE1

  9. Sep 2018 — Dec 2018 [monthly]

    Active Not Recruiting PHASE1

  10. Aug 2018 — Sep 2018 [monthly]

    Active Not Recruiting PHASE1

  11. Jun 2018 — Aug 2018 [monthly]

    Active Not Recruiting PHASE1

  12. Mar 2018 — Jun 2018 [monthly]

    Active Not Recruiting PHASE1

  13. Jun 2017 — Mar 2018 [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

  14. May 2017 — Jun 2017 [monthly]

    Recruiting PHASE1

    Status: Not Yet Recruiting → Recruiting

  15. Feb 2017 — May 2017 [monthly]

    Not Yet Recruiting PHASE1

  16. Jan 2017 — Feb 2017 [monthly]

    Not Yet Recruiting PHASE1

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Eisai Co., Ltd.
  • Merck Sharp & Dohme LLC
Data source: Eisai Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations